Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

PTX, PRESCIENT THERAPEUTICS LIMITED
mullokintyre
post Posted: Jan 14 2021, 10:46 AM
  Quote Post


Posts: 3,133
Thanks: 1130


In Reply To: nipper's post @ Aug 17 2020, 11:25 AM

Up 10% today, looking to pass thru the 52 week high.
Somebody likes it!
Mick



--------------------
sent from my Olivetti Typewriter.
 
nipper
post Posted: Aug 17 2020, 11:25 AM
  Quote Post


Posts: 7,962
Thanks: 2652


SPP extended. tracking sideways. out on the hustings.
QUOTE
Locally-listed small cap Prescient hopes to shift the conversation around cancer from treatments to cures, as it invests in a new-age technology showing early success in helping terminal patients called CAR-T.On Friday the company announced a research collaboration with the world renowned Peter MacCallum Cancer Centre to develop new cell therapy technologies to treat cancer, including CAR-T technologies. Under the terms of the research contract, Prescient will own any resultant intellectual property (IP) from the research program, which is being led by Peter Macs Professor Phil Darcy.

CAR-T is a new technique for fighting cancer that trains a patient's own immune system to recognise and attack cancer cells that have resisted standard treatments like chemotherapy or radiation. Using this approach, a person's T-cells are extracted and modified outside the body to produce special structures called chimeric antigen receptors (CARs) on their surface. These receptors are able to recognise and latch onto a specific antigen on a patient's tumour cells when they're re-injected into the body, allowing them to destroy the cells.

There's no question in my mind that it's the future. It's weaponising your own cells. Cells are the problem with cancer and they will be the answer. It's the ultimate killing machine, Prescient chief executive Steven Yatomi-Clarke said. We're the only listed company in Australia doing CAR-T... and it will be the next generation cell therapy.

Earlier this year 11-year-old Kamm Denieger's five-year battle with a rare leukaemia ended, when he became the first person in NSW to receive CAR-T therapy and a month later was deemed cancer free.

To date, CAR-T has been particularly successful in treating blood cancers. But due to the uncontrollable nature of the therapy in its current form, some cancer patients have died from CAR-T, at the same time as their cancers are killed.

T-cells can swallow up a 2 kilogram organ within a week, that's the capability of a T-cell, Mr Yatomi-Clarke said. With some end-stage cancer patients, they have no other option. But it's akin to a type of massive inflammatory response that kills COVID patients. This can be overcome though if you titrate it safely, rather than crossing your fingers and hoping a dose kills the cancer but not the patient."

There are some major barriers to CAR-T's broad adoption, which Mr Yatomi-Clarke is determined to tackle. These flaws include the fact that the treatment is extremely expensive, so far hasn't worked as well treating solid tumours (compared to blood cancers) and it's also inherently risky with patients needing to be placed in intensive care when undergoing the treatments due to the inability to control the modified T-cells while in the patient.

To help solve these flaws, Prescient is developing a platform called OmniCAR, based on technology licensed from University of Pennsylvania and Oxford University. This platform has a mechanism to allow clinicians to control the modified cell activity after infusion, including turning them off. It also enables CAR-T cells to be directed against a variety of tumours and could work with "off-the-shelf" T-cells, as well as a patient's cells.

OmniCAR is still in a preclinical phase, but Mr Yatomi-Clarke is optimistic about its future.

Anyone looking to make their CAR-T programs more controllable and safer should be speaking to us. We're going to look to monetise this sooner rather than later through collaborations and licensing. We want to be the Intel chip to others' computers, he said.


While still an emerging field, there's already been plenty of deal activity surrounding CAR-T therapies.

In 2017Gileas bought KitePharma for $US11.9 billion, ($17 billion) while in 2018 Celegne bought Juno Therapeutics for $US9 billion and in November last year Bristol Myers Squibb bought Celegne for a whopping $US74 billion.

CAR-T is not Prescient's only bet on next generation cancer therapies.

The company also has two compounds (PTX100 and PTX200) which are already in clinical trials.


PTX 100 blocks a cancer growth enzyme known as geranylgeranyl transferase-1 (GGT1), which was the first gene discovered that drives cancer development. Last week the company released results from a phase 1B dose escalation study which showed the therapy was safe in small amounts, letting the company progress to higher doses.

https://www.afr.com/policy/health-and-educa...20200803-p55i66The interesting part was even at the lowest dose, of the three patients we saw, one [person's cancer] stopped growing, and another had a partial response and their tumour actually reduced. We didn't expect to see that with the first cohort, Mr Yatomi-Clarke said.

While both PTX 100 and 200 are still early in their development, Mr Yatomi-Clarke said thanks to clever study designs (and the fact that these treatments are for patients who are dying) it would be possible to bring products to market in a relatively short amount of time, potentially after completing phase two trials. ..With refractory patients you can get to market with comparatively much smaller, much shorter development timelines, he said.

Loxo Oncology pioneered this one trial to launch... and a few guys involved in the development of their drug now work for us. It is the equivalent of doing a phase three because you're smarter with patient recruitment, he said.


https://www.afr.com/companies/healthcare-an...20200814-p55lro
















--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Aug 16 2020, 12:17 PM
  Quote Post


Posts: 7,962
Thanks: 2652


ShareCafe webinar series:


https://www.sharecafe.com.au/2020/08/14/pre...r-presentation/




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
wasabibarako
post Posted: Aug 24 2019, 03:49 PM
  Quote Post


Posts: 2,101
Thanks: 154


In Reply To: maru's post @ Apr 15 2016, 12:13 AM

maru: NO postings on this most interesting stock! I have bought a small position not too long ago, as an exciting period is ahead for PTX for certain!!

Wasabibarako

 
maru
post Posted: Apr 15 2016, 12:13 AM
  Quote Post


Posts: 9


In Reply To: maru's post @ Apr 4 2016, 02:17 AM

From this weeks presentation

Investment Summary: Why all the excitement about AML?

• Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need. » One of the worst survival rates of all cancers » Standard of care unchanged in 40 years

• A disease of intense interest for clinicians, pharma companies and investors

• Celator Pharmaceuticals (NASDAQ: CPXX) showed what can happen when enhancing the standard of care in AML » Market cap recently surged from small cap to $780M » Dr Jeff Lancet was the Principal Investigator on CPXX’s ground-breaking trial

• PTX had successful Phase 1 trial in AML (conducted at Moffitt and MD Anderson)

• Dr Lancet is also the Principal Investigator on PTX’s imminent Phase 1b/2 AML trial

• AML trial about to commence with Phase 1b results next year

 
maru
post Posted: Apr 4 2016, 02:17 AM
  Quote Post


Posts: 9


In Reply To: maru's post @ Mar 22 2016, 12:39 AM

One of Deepest Clinical Pipelines on ASX - 3 clinical trials:

2 underway and 1 on track to initiate 1H 2016, all under IND Two Clinical Stage Oncology Drugs 2 drug candidates targeting key cancer pathways » Akt (PTX-200) and Ras (PTX-100)

Distinguished Scientific Provenance Compelling science from leading US institutions – Yale University & Moffitt Cancer Center

Significant investment already made Over $20 M invested to date » Technologies have been awarded multiple prestigious US government grants

Proven Leadership & Management Experienced and proven drug development team on board to aggressively drive product development

Rich Upcoming News Flow Multiple milestone announcements and valuation inflection points across all clinical programs over next 12 to 18 months

Robust IP Patents granted in major jurisdictions extending to 2030

 


maru
post Posted: Mar 22 2016, 12:39 AM
  Quote Post


Posts: 9


In Reply To: maru's post @ Mar 10 2016, 11:08 PM

Directors holding around 11m shares which is around 12% of the 93.7m shares listed. Paul Hopper and his family owns the most with around 9m shares - interesting thing is he is Executive Chairman, Non Exec. Director of Imugene (IMU) and Chairman of Viralytics (VLA)

 
maru
post Posted: Mar 10 2016, 11:08 PM
  Quote Post


Posts: 9


Recently on Bloomberg - several days ago - link Provided below


http://www.redchip.com/media/1405/prescien...ange-of-cancers


Also updated research report

The full report can be found under the Media/Press & Research Reports tab on the Company’s website www.prescienttherapeutics.com or found on Edison Investment Limited’s website at http://www.edisoninvestmentresearch.com by clicking to the Research tab, selecting Sector Reports and under the sector Health Care.


Shares Issued: 93,741,665

Market Cap: $8,905,458

Enough cash to last till year end , stock is worth a rerate compared to others valued much higher.



 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING